List view / Grid view
30 January 2014 | By Biogen Idec
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s Innovative therapies to patients in new markets...
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
28 January 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved the Company’s supplemental new drug application for three-times-a-week COPAXONE® 40mg/mL...
28 January 2014 | By Merck
Merck said it was pleased with the positive discussion of RAGWITEK™ at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration...
28 January 2014 | By kdm communications limited
Tecan has introduced a Cavro® ADP (Air Displacement Pipettor) module for the popular Cavro Omni Robot...
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
28 January 2014 | By BMG LABTECH
When adapting a fluorescent protein assay from a confocal microscope to a microplate format, researchers no longer need filters thanks to new LVF Monochromators™ in the CLARIOstar® microplate reader from BMG LABTECH...
27 January 2014 | By Sanofi
Sanofi announced its participation in the commemoration of the 50th anniversary of diplomatic relations between France and the People's Republic of China...
27 January 2014 | By Pfizer
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC...
27 January 2014 | By Novartis
Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100...
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
24 January 2014 | By Daiichi Sankyo Company
Ranbaxy Laboratories Limited announced that the US FDA notified the company that it is prohibited from manufacturing and distributing active pharmaceutical ingredients from its facility in Toansa, India, for FDA-regulated drug products...
24 January 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Ltd. announced that the US Food and Drug Administration has issued an import alert on January 23 on Active Pharmaceutical Ingredients...
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
